J 2022

Risk of Severe COVID-19 in Non-Adherent OSA Patients

GENZOR, Samuel, Jan PRASKO, Jan MIZERA, Petr JAKUBEC, Milan SOVA et. al.

Základní údaje

Originální název

Risk of Severe COVID-19 in Non-Adherent OSA Patients

Autoři

GENZOR, Samuel (203 Česká republika), Jan PRASKO (203 Česká republika, garant), Jan MIZERA (203 Česká republika), Petr JAKUBEC (203 Česká republika), Milan SOVA (203 Česká republika, domácí), Jakub VANEK (203 Česká republika), Nikoleta SURINOVA (203 Česká republika) a Katerina LANGOVA (203 Česká republika)

Vydání

PATIENT PREFERENCE AND ADHERENCE, AUCKLAND, DOVE MEDICAL PRESS LTD, 2022, 1177-889X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.200

Kód RIV

RIV/00216224:14110/22:00128092

Organizační jednotka

Lékařská fakulta

UT WoS

000884754000001

Klíčová slova anglicky

OSA; COVID-19; vaccination; treatment with CPAP; CPAP adherence

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 18. 1. 2023 12:58, Mgr. Tereza Miškechová

Anotace

V originále

Background: Patients with obstructive sleep apnoea (OSA) are at increased risk of severe course of COVID-19. Vaccination remains to be the most effective prevention of complicated courses of infection. The best contemporary conservative treatment of OSA is continuous positive airway pressure (CPAP) therapy.Purpose: To compare vaccination acceptance and outcomes of COVID-19 infection between OSA patients adhering to the CPAP therapy and those who rejected CPAP and surgical therapy.Patients and Methods: Subjects were divided into two groups: group A (N = 167) were individuals with sufficient CPAP adherence (more than 4 hours per night on average) over the last 10 years. Group B (N = 106) were individuals who did not use the CPAP therapy at all and had no indications to surgical therapy.Results: Three patients in group B died, and one had a severe course of COVID-19. None of the patients in group A died or experienced a severe course of COVID-19. Group A had a significantly higher proportion of males (77.8% compared to 66% in group B) and all parameters of OSA severity. The vaccination status was similar among both groups, with a complete triple dose vaccination rate of 69.5% and 67.9% in groups A and B, respectively. Conclusion: The results show that the patients with OSA adherent to CPAP therapy were less likely to experience a severe course of COVID-19 or death than the OSA patients non-compliant with therapy, despite the former group having more severe OSA. This result underlines the importance of adherence to CPAP therapy in OSA.